Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Three deals worth a combined $19.5B were announced in a single day. BMS/Hengrui is the headline: $600M upfront for 13 early-stage programs is one of the boldest China licensing transactions any Western pharma company has executed. Hengrui shares surged 13% in Hong Kong on the news. The deal spans oncology, hematology, and immunology, giving BMS a broad pipeline refresh at a stage where the development risk is highest but the cost per program is lowest. This is the same playbook Lilly used with Hengrui via Kailera (obesity) and AbbVie used with Haisco (pain). Chinese biotech licensing is becoming a standard pipeline strategy for large pharma, and BMS just placed the biggest bet yet. Isomorphic Labs' $2.1B round is equally significant. This is the Google DeepMind spinout that uses AlphaFold-derived technology for drug design. One year ago, Isomorphic raised $600M in its first external round. The 3.5x step-up in 12 months signals explosive investor confidence in AI-native drug discovery. Thrive Capital led the round, and the UK Sovereign AI Fund participated, adding government backing to the thesis. Together with Anthropic's Coefficient Bio acquisition ($400M, April) and Narasimhan joining Anthropic's board, the pattern is clear: AI drug discovery is attracting the largest capital commitments in the history of computational biology. 👉 Read Full Analysis

BMS and Hengrui Partner on 13 Programs in $15.2B Deal BMY

What Happened: Bristol Myers Squibb announced a broad strategic partnership with Jiangsu Hengrui Pharmaceuticals on May 12, paying $600M upfront to co-develop 13 early-stage programs spanning oncology, hematology, and immunology. Total potential deal value, including development and commercial milestones, is up to $15.2B. BMS gains exclusive development and commercialization rights outside Greater China. Hengrui retains rights in Greater China.

The Portfolio: The 13 programs represent a diverse set of mechanisms and modalities across BMS's three core therapeutic areas. BioPharm International noted that the deal includes programs in oncology, hematology, and immunology, though specific targets and development stages for individual programs were not fully disclosed at announcement. Hengrui is one of China's largest pharmaceutical companies and has become one of the most active licensors of clinical-stage assets to Western pharma.

Executive Impact: This is the largest single China-to-West licensing transaction by total potential value in biopharma. The $600M upfront is substantial, but the real signal is the breadth: 13 programs at once suggests BMS views Hengrui as a strategic pipeline source, not a one-off licensor. Hengrui shares surged more than 13% in Hong Kong trading on the news. BMS has been under pressure to replenish its pipeline as Revlimid and Eliquis face ongoing generic erosion. This deal provides a broad set of early-stage options across the company's three priority therapeutic areas. The China licensing model is now firmly established: Lilly/Hengrui (Kailera, obesity), AbbVie/Haisco (Nav1.8, pain), GSK/SiranBio (ALK7 siRNA, obesity-adjacent), GSK/CTTQ (bepirovirsen, hepatitis), and now BMS/Hengrui ($15.2B, multi-therapeutic).

Isomorphic Labs Raises $2.1B in Largest AI Drug Discovery Round Ever

Isomorphic Labs, the London-based AI drug discovery company spun out of Google DeepMind, raised $2.1B in Series B funding. The round was led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. This follows a $600M Series A completed one year ago, bringing total funding to $2.7B. Isomorphic uses technology derived from AlphaFold, DeepMind's protein structure prediction platform that won the 2024 Nobel Prize in Chemistry. The company has existing partnerships with Eli Lilly and Novartis but has not disclosed details of its internal pipeline.

UCB Acquires Candid Therapeutics for $2.2B UCB

UCB announced a $2.2B acquisition of Candid Therapeutics, adding bispecific T-cell engager (TCE) assets targeting autoimmune diseases. The lead program, cizutamig, is a BCMA/CD3-targeting antibody in early-stage clinical trials for autoimmune conditions. This is UCB's second major acquisition in under a month, following the $1.15B Neurona Therapeutics deal (epilepsy cell therapy) announced April 17. Combined M&A deployment: more than $3.3B.

MacroGenics Sells Manufacturing to Bora Pharmaceuticals for $122.5M MGNX

MacroGenics agreed to sell its GMP manufacturing operations to Taiwanese contract manufacturer Bora Pharmaceuticals for $122.5M upfront. The Pharma Letter noted this is part of "a broader effort to slim down operations and preserve cash for its drug pipeline." The deal illustrates a growing trend: clinical-stage biotechs are divesting manufacturing assets to CDMOs rather than bearing the capital burden of maintaining in-house production. For Bora, the acquisition adds biologics manufacturing capacity in the U.S. at a time when domestic production capability is increasingly valued under the Section 232 tariff framework.

Roche Partners with PathAI for AI-Powered Cancer Diagnosis

Roche announced a partnership with PathAI to offer AI-powered pathology tools as part of its cancer diagnosis and tailored treatment offerings, according to MedTech Dive (May 7). PathAI's platform uses machine learning to analyze tissue samples, identify biomarkers, and guide treatment selection. This is one of the most concrete diagnostics-AI integrations of 2026, bridging the gap between digital pathology platforms and clinical decision-making. For oncology, AI-powered companion diagnostics could improve the speed and accuracy of biomarker-driven treatment matching, particularly for ADCs and targeted therapies where patient selection is critical to efficacy.

👉 Read Full Analysis

Western pharma companies are systematically licensing clinical-stage assets from Chinese biotechs. The deals in 2026 alone:

The strategic logic is consistent: Chinese biotechs are producing high-quality clinical-stage assets at lower development costs. Western companies get pipeline optionality. Chinese companies get upfront cash and downstream economics. The geopolitical risk is real (BIOSECURE Act concerns, Section 232 tariffs, IP transfer debates) but has not slowed deal flow. If anything, the deals are accelerating in 2026.

💊 AI Drug Discovery: The Capital Stack

The capital flowing into AI drug discovery in 2026 is unprecedented:

Total disclosed AI drug discovery capital commitments in 2026 alone exceed $8B. The thesis: AI can compress the 10 to 12 year drug development timeline by identifying better targets, designing better molecules, and predicting clinical outcomes more accurately. Whether that thesis is correct is an open question. But the capital is flowing as if it is.

📊 UCB: The Quiet Acquirer

UCB has deployed more than $3.3B in M&A in under a month:

For UCB, $3.3B in acquisitions is a significant capital commitment. UCB is building a next-generation immunology and neuroscience pipeline while its existing franchises (Bimzelx for psoriasis, Rystiggo for myasthenia gravis) generate the cash flow to fund it.

🎯 Catalyst Calendar: May 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →